Novome Biotechnologies is a biotechnology company focused on engineering defined activities into the human.
Novome Biotechnologies, Inc. is a biotechnology company focused on engineering defined activities into the human gut microbiota to treat chronic diseases. The Company has developed the first-ever platform for controlled colonization of the gut with engineered bacteria, enabling first-in-class living therapeutics: Genetically Engineered Microbial Medicines (GEMMs). Novome is utilizing its proprietary GEMMs platform in its lead preclinical program in hyperoxaluria, which is focused on the development of a therapeutic strain of bacteria that degrades oxalate to prevent the formation of kidney stones. Efforts are also directed to the expansion of its proprietary synthetic biology platform into additional indications.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Aug 16, 2018 | Grant | $1.30M | 1 |
National Science Foundation
|
— | Detail |
| Dec 8, 2016 | Grant | $225K | 1 |
National Science Foundation
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
National Science Foundation
|
Yes | Grant |